Join to View Full Profile
NANorth Bethesda, MD 20852
Dr. Prussin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1988 - 1994
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1984 - 1987
Keck School of Medicine of the University of Southern CaliforniaClass of 1984
Certifications & Licensure
MD State Medical License 1991 - 2027
CA State Medical License 1985 - 2026
MA State Medical License 2003 - 2003
American Board of Internal Medicine Internal Medicine
Clinical Trials
- Omalizumab to Treat Eosinophilic Gastroenteritis Start of enrollment: 2004 Jun 02
- Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders Start of enrollment: 2010 Aug 30
- Sirolimus for Eosinophil-Associated Gastrointestinal Disorders Start of enrollment: 2013 Mar 07
Publications & Presentations
PubMed
- 11 citationsSafety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial.Salman Siddiqui, Sally E Wenzel, Michael E Bozik, Donald G Archibald, Steven I Dworetzky
The Journal of Allergy and Clinical Immunology. 2023-11-01 - 12 citationsUrine eosinophil-derived neurotoxin: A potential marker of activity in select eosinophilic disorders.Michelle A Makiya, Paneez Khoury, Fei Li Kuang, Alexis Dominique Mata, Sana Mahmood
Allergy. 2023-01-01 - 77 citationsDexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size.Tanya M. Laidlaw, Calman Prussin, Reynold A. Panettieri, Stella E. Lee, Berrylin J. Ferguson
The Laryngoscope. 2019-02-01
Journal Articles
- Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trialSalman Siddiqui, BM, FRCP, PhD,a Sally E. Wenzel, MD,b Michael E. Bozik, MD,c Donald G. Archibald, MPhil,c Steven I. Dworetzky, PhD,c James L. Mather, BS,c Randall Kil..., Journal of Allergy and Clinical Immunology, 11/2023
Press Mentions
Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)February 28th, 2022- Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021May 17th, 2021
Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil SocietyJuly 9th, 2019
Grant Support
- Highly Differentiated Il5+ TH2 Cells In Food Allergy And Eosinophilic GI DiseaseNational Institute Of Allergy And Infectious Diseases2010–2011
- Functional And Epigenetic Analysis Of TH2 HeterogeneityNational Institute Of Allergy And Infectious Diseases2010–2011
- T Cell Pathogenesis Of Food AllergyNational Institute Of Allergy And Infectious Diseases2009
- Developmental Immunotherapeutics Of Allergic DiseasesNational Institute Of Allergy And Infectious Diseases2009
- Memory T Cell Responses To Food AllergyNational Institute Of Allergy And Infectious Diseases2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
